Trials / Unknown
UnknownNCT05474950
Minocycline Treatment for Cystoid Macular Edema
Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | minocycline | minocycline capsule (100mg) per day orally |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2024-06-01
- Completion
- 2025-06-01
- First posted
- 2022-07-26
- Last updated
- 2023-04-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05474950. Inclusion in this directory is not an endorsement.